🇺🇸 FDA
Pipeline program

NKTR-181

18-181-26

Phase 1 small_molecule terminated

Quick answer

NKTR-181 for Moderate to Severe Chronic Pain is a Phase 1 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Moderate to Severe Chronic Pain
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials